Kinetic oscillation stimulation as treatment of acute migraine: a randomized, controlled pilot study

Jan-Erik Juto, Rolf G Hallin, Jan-Erik Juto, Rolf G Hallin

Abstract

Objective: To assess the relief of migraine pain, especially in the acute phase, by comparing active treatment, ie, kinetic oscillation stimulation (KOS) in the nasal cavity, with placebo.

Background: Exploratory trials testing the efficacy of KOS on migraine patients indicated that this treatment could be a fast-acting remedy for acute migraine pain.

Method: Thirty-six patients were randomized 1:1 using a placebo module to active or placebo treatment in this double-blinded parallel design study. Treatment was administered with a minimally invasive inflatable tip oscillating catheter. Symptom scores (0-10 visual analog scale) were obtained before treatment, every 5 minutes during treatment, at 15 minutes, 2, and 24 hours post-treatment, as well as daily (0-3 migraine pain scale) from 30 days pretreatment until Day 60 post. Thirty-five patients were evaluated (active n=18, placebo n=17). The primary end-point was the change in average pain score from before treatment to 15 minutes after treatment.

Results: Patients who received active treatment reported reduced pain, eg, average visual analog scale pain scores fell from 5.5 before treatment to 1.2 15 minutes after, while the corresponding scores for recipients of placebo fell from 4.9 to 3.9. The changes in pain scores differed between the 2 treatments by 3.3 points (95% confidence interval: 2.3, 4.4), P<.001. Already 5 minutes into the treatment, the difference (1.9 points) was significant (P=.007). The difference was likewise significant at 2 hours post-treatment (3.7 points, P<.001). One patient experienced an adverse event (a vasovagal reaction with full spontaneous recovery) during placebo treatment.

Conclusion: KOS is an effective and safe treatment for acute migraine pain.

Trial registration: ClinicalTrials.gov NCT01880671.

Keywords: autonomic nervous system; kinetic oscillation stimulation; medical device; migraine; minimally invasive; neuromodulation.

© 2014 The Authors. Headache published by Wiley Periodicals, Inc. on behalf of American Headache Society.

Figures

Fig 1
Fig 1
Treatment catheter in plastic bag.
Fig 2
Fig 2
Catheter inserted into nasal cavity and secured with headband.
Fig 3
Fig 3
CONSORT flow diagram.
Fig 4
Fig 4
Individual visual analog scale (VAS) scores by minute during procedure in patients receiving active treatment.
Fig 5
Fig 5
Individual visual analog scale (VAS) scores by minute during procedure in patients receiving placebo treatment.

References

    1. Goadsby PJ, Lipton RB, Ferrari MD. Migraine – Current understanding and treatment. N Engl J Med. 2002;346:257–270.
    1. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22:633–658.
    1. Cady RK, Aurora SK, Brandes JL. Satisfaction with and confidence in needle-free subcutaneous sumatriptan in patients currently treated with triptans. Headache. 51:1202–1211.
    1. Lantéri-Minet M, Mick G, Allaf B. Early dosing and efficacy of triptans in acute migraine treatment: The TEMPO study. Cephalalgia. 2012;32:226–235. 2011.
    1. Láinez M. Clinical benefits of early triptan therapy for migraine. Cephalalgia. 2004;24:24–30.
    1. Maizels M, Geiger AM. Intranasal lidocaine for migraine: A randomized trial and open-label follow-up. Headache. 1999;39:543–551.
    1. Sluder G. The anatomical and clinical relations of the sphenopalatine (Meckel's) ganglion to the nose and its accessory sinuses. NY Med J. 1909;28:293–298.
    1. Juto JE, Axelsson M. Kinetic oscillation stimulation as treatment of non-allergic rhinitis: An RCT study. Acta Otolaryngol. 2014;134:506–512.
    1. Martelletti P, Jensen RH, Antal A. Neuromodulation of chronic headaches: Position statement from the European Headache Federation. J Headache Pain. 2013;14:86.
    1. Tfelt-Hansen P, Pascual J, Ramadan N. Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators. Cephalalgia. 2012;32:6–38.
    1. Avnon Y, Nitzan M, Sprecher E, Rogowski Z, Yarnitsky D. Different patterns of parasympathetic activation in uni- and bilateral migraineurs. Brain. 2003;126:1660–1670.
    1. Goadsby PJ, Lipton RB. A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic feature, including new cases. Brain. 1997;120(Pt 1):193–209.
    1. Alstadhaug KB. Migraine and the hypothalamus. Cephalalgia. 2009;29:809–817.
    1. Kahn S, Schoenen J, Ashina M. Sphenopalatine ganglion neuromodulation in migraine: What is the rationale? Cephalalgia. 2014;34:382–391.
    1. Jenkins B, Tepper SJ. Neurostimulation for primary headache disorders, part 1: Pathophysiology and anatomy, history of neuromodulation in headache treatment, and review of peripheral neuromodulation in primary headaches. Headache. 2011;51:1254–1266.
    1. Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011;12:570–584.
    1. Schoenen J, Højland Jensen R, Lantéri-Minet M. Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: A randomized, sham-controlled study. Cephalalgia. 2013;33:816–830.

Source: PubMed

3
Abonnere